Approval · Notice of Compliance 16219 · 2014
DUAVIVE: Notice of Compliance 16219
Issued October 23, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16219
- Date
- October 23, 2014
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Estrogenic Hormones and Selective Estrogen Receptor Modulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DUAVIVE | Not yet assigned | — |
| DUAVIVE | 02432854 | Marketed |
Medicinal ingredients
- CONJUGATED ESTROGENS 0.45 MG per TAB
- BAZEDOXIFENE ACETATE 20 MG per TAB